144 related articles for article (PubMed ID: 11669411)
1. The EUROPA trial: design, baseline demography and status of the substudies.
Gomma AH; Fox KM
Cardiovasc Drugs Ther; 2001 Mar; 15(2):169-79. PubMed ID: 11669411
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).
Fox KM;
Lancet; 2003 Sep; 362(9386):782-8. PubMed ID: 13678872
[TBL] [Abstract][Full Text] [Related]
3. Effects of perindopril on long-term clinical outcome of patients with coronary artery disease and preserved left ventricular function.
Bertrand ME; Remme WJ; Fox KM; Ferrari R; Simoons ML;
Int J Cardiol; 2007 Sep; 121(1):57-61. PubMed ID: 17270296
[TBL] [Abstract][Full Text] [Related]
4. PERindopril-Function of the Endothelium in Coronary Artery Disease Trial: the PERFECT study--sub study of EUROPA: rationale and design.
Bots ML; Remme WJ; Lüscher TF; Grobbee DE;
Cardiovasc Drugs Ther; 2002 May; 16(3):227-36. PubMed ID: 12374901
[TBL] [Abstract][Full Text] [Related]
5. Costs and effects of secondary prevention with perindopril in stable coronary heart disease in Poland: an analysis of the EUROPA study including 1251 Polish patients.
Redekop WK; Orlewska E; Maciejewski P; Rutten FF; Niessen LW
Pharmacoeconomics; 2008; 26(10):861-77. PubMed ID: 18793033
[TBL] [Abstract][Full Text] [Related]
6. The European trial on reduction of cardiac events with perindopril in stable coronary artery disease (EUROPA).
Fox KM; Henderson JR; Bertrand ME; Ferrari R; Remme WJ; Simoons ML
Eur Heart J; 1998 Sep; 19 Suppl J():J52-5. PubMed ID: 9796841
[TBL] [Abstract][Full Text] [Related]
7. Perindopril and β-blocker for the prevention of cardiac events and mortality in stable coronary artery disease patients: A EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) subanalysis.
Bertrand ME; Ferrari R; Remme WJ; Simoons ML; Fox KM
Am Heart J; 2015 Dec; 170(6):1092-8. PubMed ID: 26678630
[TBL] [Abstract][Full Text] [Related]
8. PERTINENT--perindopril-thrombosis, inflammation, endothelial dysfunction and neurohormonal activation trial: a sub-study of the EUROPA study.
Scientific Committee of the PERTINENT Sub-Study, EUROPA-PERTINENT Investigators
Cardiovasc Drugs Ther; 2003 Jan; 17(1):83-91. PubMed ID: 12843690
[TBL] [Abstract][Full Text] [Related]
9. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy.
Daly CA; Fox KM; Remme WJ; Bertrand ME; Ferrari R; Simoons ML;
Eur Heart J; 2005 Jul; 26(14):1369-78. PubMed ID: 15860521
[TBL] [Abstract][Full Text] [Related]
10. ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT.
Ceconi C; Fox KM; Remme WJ; Simoons ML; Bertrand M; Parrinello G; Kluft C; Blann A; Cokkinos D; Ferrari R; ;
Cardiovasc Res; 2007 Jan; 73(1):237-46. PubMed ID: 17140552
[TBL] [Abstract][Full Text] [Related]
11. [Angiotensin-converting enzyme inhibitors in patients with preserved left ventricular function: from EUROPA to PREAMI].
Ferrari R; Papa K; Bernocchi P; Gimbatti OJ; Golcea SS; Bettini A; Ceconi C
Ital Heart J; 2005 Nov; 6 Suppl 7():24S-32S. PubMed ID: 16485514
[TBL] [Abstract][Full Text] [Related]
12. EUROPA substudies, confirmation of pathophysiological concepts. European trial on reduction of cardiac events with perindopril in stable coronary artery disease.
Simoons ML; Vos J; de Feyter PJ; Bots ML; Remme WJ; Grobbee DE; Kluft C; de Maat MP; Fox KM; Deckers JW
Eur Heart J; 1998 Sep; 19 Suppl J():J56-60. PubMed ID: 9796842
[TBL] [Abstract][Full Text] [Related]
13. [Rationale, characteristics and study design of PREAMI (Perindopril and Remodelling in the Elderly with Acute Myocardial Infraction)].
Magrini G; Nicolosi GL; Chiariello M; Ferrari R; Remme P; Tavazzi L
Ital Heart J; 2005 Nov; 6 Suppl 7():14S-23S. PubMed ID: 16485513
[TBL] [Abstract][Full Text] [Related]
14. ACE inhibition and endothelial function: main findings of PERFECT, a sub-study of the EUROPA trial.
Bots ML; Remme WJ; Lüscher TF; Fox KM; Bertrand M; Ferrari R; Simoons ML; Grobbee DE;
Cardiovasc Drugs Ther; 2007 Aug; 21(4):269-79. PubMed ID: 17657599
[TBL] [Abstract][Full Text] [Related]
15. VALIANT and EUROPA.
Liebson PR
Prev Cardiol; 2004; 7(1):42-4. PubMed ID: 15010627
[No Abstract] [Full Text] [Related]
16. Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study.
Briggs A; Mihaylova B; Sculpher M; Hall A; Wolstenholme J; Simoons M; Deckers J; Ferrari R; Remme WJ; Bertrand M; Fox K;
Heart; 2007 Sep; 93(9):1081-6. PubMed ID: 17135223
[TBL] [Abstract][Full Text] [Related]
17. [Clinical study of the month. The EUROPA study: cardiovascular protection with perindopril in patients with stable coronary heart disease].
Scheen AJ; Legrand V
Rev Med Liege; 2003 Nov; 58(11):713-6. PubMed ID: 14748202
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin-converting enzyme inhibition with perindopril in patients with prior myocardial infarction and/or revascularization: a subgroup analysis of the EUROPA trial.
Bertrand ME; Fox KM; Remme WJ; Ferrari R; Simoons ML
Arch Cardiovasc Dis; 2009 Feb; 102(2):89-96. PubMed ID: 19303575
[TBL] [Abstract][Full Text] [Related]
19. EUROPA: clinical benefits, clinical promise.
Cardiovasc J S Afr; 2004; 15(3):147. PubMed ID: 15356915
[No Abstract] [Full Text] [Related]
20. [Hypertension, heart failure, myocardial infarction, secondary prevention: the role of perindopril].
Rapezzi C; Ciliberti P; Graziosi M; Riva L
Ital Heart J; 2005 Nov; 6 Suppl 7():40S-47S. PubMed ID: 16485516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
